Dartmouth-Hitchcock doctors use new treatment options for prostate cancer
“The study shows the toxicity is quite reasonable and pretty low,” Sroka said.
The treatment is for patients with symptomatic metastatic castration-resistant prostate cancer that has spread to bones, but not to other organs.
According to the Norris Cotton Cancer Center, “Prostate cancer is the most common cancer among men in the United States. If it spreads to other places in the body, prostate cancer predominantly settles in the bones. Bone metastases are a leading cause of death in men with prostate cancer.”
The drug is administered intravenously in six treatments every four weeks. So the treatment takes place over a six month period. The agent is made to look like calcium so it is easily absorbed into the bone, Sroka said.
The agent provides a targeted radiation treatment in the bone. The settled agent doesn’t travel far, Sroka said, less than 100 micrometers. So its ability to damage surrounding normal tissue is limited, he said.
The agent is only radioactive for a short time and then usually passes through the body, he said.
Sroka said he currently has three patients, who are still receiving the treatment. In his cases the treatment has reduced pain and the side effects have been manageable.
The most common side effects are nausea, diarrhea, vomiting, and peripheral edema.
Sroka is a member of Norris Cotton Cancer Center’s Prostate and Genitourinary Cancer Program with specialized interest in prostate brachytherapy, intensity modulation radiation therapy, and stereotactic radiosurgery. He offers radium-223 injections at Norris Cotton Cancer Center in Lebanon.
NH's future: Dean Kamen highlights a problem